BIO-TECHNE Corp — Director's Dealing 2021

Aug 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-08-06

Reporting Person: Hippel James (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-08	Common Stock	M	3383	—	Acquired	12520	Direct
2021-08-08	Common Stock	F	1665	$481.82	Disposed	10855	Direct
2021-08-09	Common Stock	M	10000	$106.59	Acquired	20855	Direct
2021-08-09	Common Stock	S	5200	$477.6926	Disposed	15655	Direct
2021-08-09	Common Stock	S	1800	$478.58	Disposed	13855	Direct
2021-08-09	Common Stock	S	1300	$479.9644	Disposed	12555	Direct
2021-08-09	Common Stock	S	100	$480.7	Disposed	12455	Direct
2021-08-09	Common Stock	S	700	$480.6607	Disposed	11755	Direct
2021-08-09	Common Stock	S	300	$481.605	Disposed	11455	Direct
2021-08-09	Common Stock	S	300	$483.6167	Disposed	11155	Direct
2021-08-09	Common Stock	S	300	$484.9792	Disposed	10855	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-09	Stock Options (Right to Buy)	$106.59	M	10000	Disposed	2023-08-18	Common Stock (10000)	Direct
2021-08-08	Restricted Stock Units	$	M	3383	Disposed		Common Stock (3383)	Direct
2021-08-06	Restricted Stock Units	$	A	1945	Acquired		Common Stock (1945)	Direct
2021-08-06	Stock Options (Right to Buy)	$481.82	A	7600	Acquired	2028-08-06	Common Stock (7600)	Direct
2021-08-06	Stock Options (Right to Buy)	$481.82	A	10134	Acquired	2028-08-06	Common Stock (10134)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$125.05	2024-08-09	Common Stock (24460)	24460	Direct
Stock Options (Right to Buy)	$125.05	2024-08-09	Common Stock (32613)	32613	Direct
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (18066)	18066	Direct
Stock Options (Right to Buy)	$177.32	2025-08-08	Common Stock (24089)	24089	Direct
Restricted Stock Units	$		Common Stock (3938)	3938	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (19936)	19936	Direct
Stock Options (Right to Buy)	$190.41	2026-08-07	Common Stock (26581)	26581	Direct
Restricted Stock Units	$		Common Stock (3219)	3219	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (14360)	14360	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (19147)	19147	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (8325)	8325	Direct
Stock Options (Right to Buy)	$267.87	2027-08-05	Common Stock (8325.0)	8325.0	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $477.20 to $478.13, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $478.25 to $479.12, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.69 to $480.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.70 to $480.70, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.23 to $481.185, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.49 to $481.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.59 to $483.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.64 to $485.4475, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

F10: Fully exercisable.

F11: Vested in full on 8/8/2021 upon the certification of achievement of performance goals.

F12: Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022.

F13: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F14: Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.

F15: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F16: Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.

F17: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

F18: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F19: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F20: Options to purchase 2,534 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vest on each of 8/6/2024 and 8/6/2025.